JP7129973B2 - ブロモドメイン阻害剤 - Google Patents

ブロモドメイン阻害剤 Download PDF

Info

Publication number
JP7129973B2
JP7129973B2 JP2019521064A JP2019521064A JP7129973B2 JP 7129973 B2 JP7129973 B2 JP 7129973B2 JP 2019521064 A JP2019521064 A JP 2019521064A JP 2019521064 A JP2019521064 A JP 2019521064A JP 7129973 B2 JP7129973 B2 JP 7129973B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
cancer
methylisoquinolin
methylsulfonylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535671A (ja
JP2019535671A5 (zh
Inventor
ジュアン マヌエル ベタンコート
ジェフリー アラン スタッフォード
ライアン スタンフィールド
ジェームズ マーヴィン ヴィール
Original Assignee
セルジーン クオンティセル リサーチ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン クオンティセル リサーチ，インク． filed Critical セルジーン クオンティセル リサーチ，インク．
Publication of JP2019535671A publication Critical patent/JP2019535671A/ja
Publication of JP2019535671A5 publication Critical patent/JP2019535671A5/ja
Priority to JP2022066855A priority Critical patent/JP2022095897A/ja
Application granted granted Critical
Publication of JP7129973B2 publication Critical patent/JP7129973B2/ja
Priority to JP2024021416A priority patent/JP2024056905A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019521064A 2016-10-20 2017-10-19 ブロモドメイン阻害剤 Active JP7129973B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022066855A JP2022095897A (ja) 2016-10-20 2022-04-14 ブロモドメイン阻害剤
JP2024021416A JP2024056905A (ja) 2016-10-20 2024-02-15 ブロモドメイン阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410756P 2016-10-20 2016-10-20
US62/410,756 2016-10-20
PCT/US2017/057439 WO2018075796A1 (en) 2016-10-20 2017-10-19 Bromodomain inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022066855A Division JP2022095897A (ja) 2016-10-20 2022-04-14 ブロモドメイン阻害剤

Publications (3)

Publication Number Publication Date
JP2019535671A JP2019535671A (ja) 2019-12-12
JP2019535671A5 JP2019535671A5 (zh) 2020-10-22
JP7129973B2 true JP7129973B2 (ja) 2022-09-02

Family

ID=62019669

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019521064A Active JP7129973B2 (ja) 2016-10-20 2017-10-19 ブロモドメイン阻害剤
JP2022066855A Pending JP2022095897A (ja) 2016-10-20 2022-04-14 ブロモドメイン阻害剤
JP2024021416A Pending JP2024056905A (ja) 2016-10-20 2024-02-15 ブロモドメイン阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022066855A Pending JP2022095897A (ja) 2016-10-20 2022-04-14 ブロモドメイン阻害剤
JP2024021416A Pending JP2024056905A (ja) 2016-10-20 2024-02-15 ブロモドメイン阻害剤

Country Status (7)

Country Link
EP (1) EP3528810A4 (zh)
JP (3) JP7129973B2 (zh)
CN (1) CN110099685A (zh)
AR (1) AR109859A1 (zh)
AU (1) AU2017345468B2 (zh)
TW (1) TW201821062A (zh)
WO (1) WO2018075796A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
BR112021001019A2 (pt) * 2018-07-23 2021-04-13 Celgene Quanticel Research, Inc. Processo para a preparação de inibidor de bromodomínio

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058160A1 (en) 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
WO2015078929A1 (en) 2013-11-27 2015-06-04 Oncoethix Sa Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
JP2016529246A (ja) 2013-08-06 2016-09-23 オンコエシックス ゲーエムベーハー Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US9884806B2 (en) * 2013-08-30 2018-02-06 Icahn School Of Medicine At Mount Sinai Cyclic vinylogous amides as bromodomain inhibitors
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
CN105732624B (zh) * 2016-01-28 2019-08-02 中国药科大学 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529246A (ja) 2013-08-06 2016-09-23 オンコエシックス ゲーエムベーハー Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法
WO2015058160A1 (en) 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
WO2015078929A1 (en) 2013-11-27 2015-06-04 Oncoethix Sa Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
森部久仁一、山本恵司，非晶質医薬品の調製と評価，低温生物工学会誌，2005年，Vol.51, No.1，p.19-24
難水溶性薬物の経口製剤化技術最前線，株式会社シーエムシー出版，2016年07月，p.64,127-135

Also Published As

Publication number Publication date
JP2022095897A (ja) 2022-06-28
AU2017345468A1 (en) 2019-06-06
AU2017345468B2 (en) 2022-06-02
WO2018075796A1 (en) 2018-04-26
JP2019535671A (ja) 2019-12-12
AR109859A1 (es) 2019-01-30
CN110099685A (zh) 2019-08-06
EP3528810A4 (en) 2020-06-17
TW201821062A (zh) 2018-06-16
EP3528810A1 (en) 2019-08-28
JP2024056905A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
CA2983446C (en) Bromodomain inhibitor
JP2024056905A (ja) ブロモドメイン阻害剤
CN113226302B (zh) 用于治疗或预防痛风或高尿酸血症的化合物的晶型
JP2022510303A (ja) 痛風または高尿酸血症を処置または予防するための方法
CA3140412A1 (en) Compound for treating gout or hyperuricemia
US20230301983A1 (en) Bromodomain inhibitor
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP7397487B2 (ja) 感覚有毛細胞死を予防または処置するための化合物の結晶形態
CN112438978B (zh) 一种西达本胺药物组合物及其制备方法和应用
EA043666B1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220414

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220414

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20220415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220418

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220517

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220622

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220726

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220823

R150 Certificate of patent or registration of utility model

Ref document number: 7129973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150